Kinase inhibition in autoimmunity and inflammation Zaron et al. 2020

Jaybee00 · Nov 21, 2020

https://www.nature.com/articles/s41573-020-0082-8

Abstract
Despite recent advances in the treatment of autoimmune and inflammatory diseases, unmet medical needs in some areas still exist. One of the main therapeutic approaches to alleviate dysregulated inflammation has been to target the activity of kinases that regulate production of inflammatory mediators. Small-molecule kinase inhibitors have the potential for broad efficacy, convenience and tissue penetrance, and thus often offer important advantages over biologics. However, designing kinase inhibitors with target selectivity and minimal off-target effects can be challenging. Nevertheless, immense progress has been made in advancing kinase inhibitors with desirable drug-like properties into the clinic, including inhibitors of JAKs, IRAK4, RIPKs, BTK, SYK and TPL2. This Review will address the latest discoveries around kinase inhibitors with an emphasis on clinically validated autoimmunity and inflammatory pathways.
Click to expand...

Log in or Sign up

Kinase inhibition in autoimmunity and inflammation Zaron et al. 2020

Jaybee00 Senior Member (Voting Rights)

Share This Page

Log in or Sign up

Kinase inhibition in autoimmunity and inflammation Zaron et al. 2020

Jaybee00 Senior Member (Voting Rights)

Share This Page

Useful Searches